Table 2 Cox proportional Hazards models for estimating the effect on time to recurrence

All patients

   CCND1, amplified vs. nonamplified

2.04 (1.37 to 3.03)

10.51

< 0.001

1.61 (1.08 to 2.41)

4.86

0.030

   Cyclin D₁ cytoplasmic intensity, high vs. remainder

0.71 (0.51 to 0.98)

4.43

0.039

0.78 (0.56 to 1.09)

2.15

0.143

   Cyclin D₁ nuclear intensity, high vs. remainder

0.91 (0.64 to 1.28)

0.30

0.588

0.85 (0.59 to 1.21)

0.84

0.360

   Cyclin D₁ nuclear fraction, 1 to 100% vs. < 1%

0.58 (0.38 to 0.90)

5.28

0.014

0.60 (0.39 to 0.92)

4.75

0.030

Nonamplified patients

   Cyclin D₁ cytoplasmic intensity, high vs. remainder

0.57 (0.39 to 0.82)

9.57

0.003

0.64 (0.44 to 0.95)

5.21

0.022

   Cyclin D₁ nuclear intensity, high vs. remainder

0.88 (0.60 to 1.32)

0.38

0.545

0.84 (0.55 to 1.26)

0.76

0.382

   Cyclin D₁ nuclear fraction, 1 to 100% vs. < 1%

0.52 (0.34 to 0.81)

7.29

0.004

0.54 (0.35 to 0.85)

6.36

0.012